Search
Semaglutide Treatment Options
A collection of 194 research studies where Semaglutide is the interventional treatment. These studies are located in the United States . Semaglutide is used for conditions such as Diabetes Mellitus, Type 2, Obesity and Diabetes.
25 - 36 of 194
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk
Active Not Recruiting
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Type 2 Diabetes, Overweight, Cardiovascular (CV) Risk
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
Recruiting
The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/01/2025
Locations: The University of Arizona College of Medicine- Phoenix, Phoenix, Arizona +1 locations
Conditions: Overweight or Obesity, Atrial Fibrillation
Semaglutide Therapy for Alcohol Reduction (STAR)
Recruiting
Background:
Alcohol use disorder (AUD) is a problematic pattern of alcohol use accompanied by clinically significant medical consequences. Medications can help most people reduce their drinking, but the number is limited, and additional treatment options are needed.
Objective:
To test if a medication named Semaglutide is safe and may reduce alcohol drinking in people with AUD.
Who can participate?
All Adults aged 18 or older with AUD might be eligible to participate in the study.
What will... Read More
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
07/31/2025
Locations: National Institute on Drug Abuse, Baltimore, Maryland
Conditions: Addiction, Alcohol Use Disorder
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
Completed
This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance.
The study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: John Muir Physicians Network, Concord, California +174 locations
Conditions: Overweight, Obesity, Type 2 Diabetes Mellitus
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Active Not Recruiting
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either dr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Univ of Alabama_Birmingham, Birmingham, Alabama +175 locations
Conditions: Type 2 Diabetes
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Active Not Recruiting
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSem... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/30/2025
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +225 locations
Conditions: Obesity
Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures
Enrolling By Invitation
The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity. The Secondary Objective: To assess the impact of these therapies on weight management practices and metabolic health.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/28/2025
Locations: AgelessRx, Ann Arbor, Michigan
Conditions: Longevity, Quality of Life, Mood, Inflammation, Immune Health, Pain Management, Weight Management, Alertness
ADJUnct Semaglutide Treatment in Type 1 Diabetes
Completed
The purpose of this study is to assess the use of once weekly semaglutide injection in inadequately controlled obese adults with type 1 diabetes (T1D) using FDA-approved hybrid closed-loop therapies.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/27/2025
Locations: Barbara Davis Center for Diabetes, Aurora, Colorado +3 locations
Conditions: Type 1 Diabetes, Obesity
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Active Not Recruiting
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors. The study will compare CagriSema to the 2 medicines semaglutide and cagrilintide, when they are taken alone. It will also compare CagriSema to a "dummy" medicine (also called placebo) without any active ingredient. Participant will either get CagriSema, se... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: John Muir Physicians Network, Concord, California +119 locations
Conditions: Chronic Kidney Disease, Type 2 Diabetes, Obesity
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
Active Not Recruiting
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected br... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/22/2025
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +566 locations
Conditions: Cardiovascular Disease
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
Active Not Recruiting
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Gender:
ALL
Ages:
All
Trial Updated:
07/15/2025
Locations: Research Site, Mobile, Alabama +96 locations
Conditions: Diabetes Mellitus, Type 2
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Recruiting
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: eStudySite, La Mesa, California +49 locations
Conditions: Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
25 - 36 of 194